Global Methicillin-resistant Staphylococcus Aureus Drugs Market Size (2024 - 2029)

The Methicillin-resistant Staphylococcus Aureus drugs market is anticipated to experience growth due to the increasing prevalence of MRSA infections, which have been exacerbated by the COVID-19 pandemic. The rise in hospital-associated MRSA infections, particularly in vulnerable populations such as the elderly and those with organ dysfunction, is expected to drive demand for these drugs. Despite the challenges posed by limited surveillance in developing countries, the market is poised for expansion as healthcare systems continue to address the threats posed by multidrug-resistant organisms.

Market Size of Global Methicillin-resistant Staphylococcus Aureus Drugs Industry

Methicillin-resistant Staphylococcus Aureus Drugs Market
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 3.60 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Global Methicillin-resistant Staphylococcus Aureus Drugs Market Major Players

*Disclaimer: Major Players sorted in no particular order

Methicillin Resistant Staphylococcus Aureus Drugs Market Analysis

The Methicillin-resistant Staphylococcus Aureus Drugs Market is expected to register a growth at a CAGR of 3.6% during the forecast period.

The global healthcare system has faced unprecedented challenges as a result of the coronavirus disease 2019 (COVID-19) pandemic, with opportunistic and secondary infections being one of the most serious issues. Due to exposure to multidrug-resistant organisms in healthcare facilities, the majority of secondary infections develop as nosocomial infections. According to the study "Impact of the COVID-19 Pandemic on the Incidence of Multidrug-Resistant Bacterial Infections in an Acute Care Hospital in Brazil" published in "American Journal of Infection Control" in September 2021, researchers identified 8,869 healthcare-associated infections (HCAI) caused by multidrug-resistant (MDR) bacteria that contributed to the higher mortality rate in Brazil. According to the findings, out of 8,869 HCAIs, of which 2,641 (29.7%) were caused by multidrug-resistant (MDR), and 1,257 (14.1%) were from ICUs. The overall incidence density (ID) of MDR infections increased by 23% during COVID-19. The total per-pathogen study reveals large increases in methicillin-resistant Staphylococcus aureus (MRSA) infections (+94.7%) and carbapenem-resistant Acinetobacter baumannii (CRAB) infections (+108.1%). In the ICU, the overall ID of MDR infections decreased during COVID, but that decline was not significant. The ICU per-pathogen analysis of ID of infection showed significant increases in CRAB and MRSA i.e. +42.0%, and +46.2% respectively. Therefore, the COVID-19 pandemic correlates to an increase in the ID of MRSA both in ICU and non-ICU settings. Thus, the possible outbreaks of MRSA in hospital settings are expected to create lucrative opportunities for the global Methicillin-resistant Staphylococcus Aureus Drugs market growth in the studied period.

The key factors attributing to the growth of the Methicillin-resistant Staphylococcus Aureus (MRSA) drugs market are a rise in the global prevalence of MRSA infections. According to the study "Methicillin-Resistant Staphylococcus Aureus" published in July 2021, the study indicated that MRSA appears to increase mortality and morbidity in geriatric people, nursing home patients, and people with organ dysfunction. People with end-stage liver disease, renal disease, and those hospitalized in the ICU have a significant chance to get hospital-associated MRSA. As per the findings, depending on the patient group and infection site, fatality rates range from 5 to 60%. Furthermore, researchers concluded that despite having no healthcare risks, over 60% of patients get MRSA within 48 hours of hospitalization. Hence, these factors are expected to increase the demand for MRSA drugs, in turn, it will create lucrative opportunities for the taget market growth in the given timeframe.

However, in developing countries, a lack of comprehensive surveillance for MRSA infection is expected to limit the market growth for MRSA drugs during the forecast period.

Methicillin Resistant Staphylococcus Aureus Drugs Industry Segmentation

As per the scope of the report, methicillin-resistant staphylococcus aureus (MRSA) is an infection caused by antibiotic-resistant strains of the pathogen Staphylococcus Aureus. The Methicillin-resistant Staphylococcus Aureus Drugs Market is segmented by Drug Class (Oxazolidinones, Lipopeptides, Cephalosporin, Tetracycline, Folate Antagonist, Other Drug Classes), Route of Administration (Oral Administration and Parenteral Administration ), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the market size and forecasts in value (USD million) for the above segments.

By Drug Class
Lipopeptides
Oxazolidinones
Cephalosporin
Tetracycline
Folate Antagonist
Other Drug Classes
By Route of Administration
Oral Administration
Parenteral Administration
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Methicillin-resistant Staphylococcus Aureus Drugs Market Size Summary

The Methicillin-resistant Staphylococcus Aureus (MRSA) drugs market is poised for growth, driven by the increasing prevalence of MRSA infections globally. The COVID-19 pandemic has exacerbated the situation, with a notable rise in healthcare-associated infections due to multidrug-resistant organisms, including MRSA. This surge in infections, particularly in hospital settings, is expected to create significant opportunities for market expansion. The demand for MRSA drugs is further fueled by the high morbidity and mortality rates associated with these infections, especially among vulnerable populations such as the elderly and those with underlying health conditions. Despite the challenges posed by limited surveillance in developing countries, the market is supported by advancements in antibiotic therapies, including lipopeptides and novel antimicrobials, which are crucial in combating MRSA.

North America is anticipated to lead the MRSA drugs market, bolstered by robust healthcare infrastructure and government initiatives aimed at addressing antibiotic resistance. The region's proactive measures, such as the National Action Plan by the United States Centers for Disease Control and Prevention, underscore the commitment to tackling MRSA infections. Key industry players, including Pfizer Inc. and Melinta Therapeutics Inc., are actively contributing to market growth through the development and launch of targeted therapies. These efforts, combined with the rising burden of MRSA infections, are expected to drive the market forward during the forecast period.

Explore More

Global Methicillin-resistant Staphylococcus Aureus Drugs Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increased Prevalence of Global Infections and Demand for Novel Therapies

      2. 1.2.2 Rise in Research Activities to Develop Novel MRSA Drugs by Key Players and Support by Government Initiatives

    3. 1.3 Market Restraints

      1. 1.3.1 Lack of Systematic Surveillance for MRSA Infection in Developing Countries

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD Million)

    1. 2.1 By Drug Class

      1. 2.1.1 Lipopeptides

      2. 2.1.2 Oxazolidinones

      3. 2.1.3 Cephalosporin

      4. 2.1.4 Tetracycline

      5. 2.1.5 Folate Antagonist

      6. 2.1.6 Other Drug Classes

    2. 2.2 By Route of Administration

      1. 2.2.1 Oral Administration

      2. 2.2.2 Parenteral Administration

    3. 2.3 By Distribution Channel

      1. 2.3.1 Hospital Pharmacies

      2. 2.3.2 Retail Pharmacies

      3. 2.3.3 Online Pharmacies

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle-East and Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of Middle-East and Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

Global Methicillin-resistant Staphylococcus Aureus Drugs Market Size FAQs

The Global Methicillin-resistant Staphylococcus Aureus Drugs Market is projected to register a CAGR of 3.60% during the forecast period (2024-2029)

Pfizer Inc, Cumberland Pharmaceuticals Inc, Melinta Therapeutics Inc, Merck & Co Inc and AbbVie Inc. are the major companies operating in the Global Methicillin-resistant Staphylococcus Aureus Drugs Market.

Methicillin-resistant Staphylococcus Aureus Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)